In 2018, Dr. Teri Greiling, a dermatologist at Oregon Health and Science University, embarked on a research project to investigate the clinical response and safety of ixekizumab (brand name Taltz®) in treating for moderate to severe pityriasis rubra pilaris.
The research was described as a single-arm, investigator-initiated trial conducted in adult patients with moderate to severe pityriasis rubra pilaris.
✱ Patients screened: 41
✱ Patients enrolled: 12
✱ Patients completing therapy: 11
✱ Treatment period: 24 weeks
The data developed by Dr. Greiling supports a finding that “ixekizumab was associated with reduced clinical signs and symptoms of PRP in a subset of patients, including those in whom other systemic therapies have failed.” This is a very good outcome.
Not only was ixekizumab associated with decreased clinical signs and symptoms of PRP, but there were “no serious adverse events”.
Scoring is the Name of the Game
This is where need more space to understand what the data shows.
Psoriasis Area and Severity Index Scoring
For example, Dr. Greiling’s date reports a “mean change in PASI at 24 weeks. Seven of the 12 participants achieved a 50% or greater reduction in clinical severity. ” Huh? Perhaps we need to understand what what it actually means. Learn more about PASI.
Dermatology Life Quality Index Scoring
What is the DLQI? The UCLA PRP Study evaluated 574 PRP patients in 2018 . Perhaps we should understand this scoring tool. Learn more about DLQI
Itch Scoring
There are two ways to quantify the discomfort associated with itching. Do you have an itch to know more? Learn more about the 12-item scale and the 5-D scale
Pain Scoring
On a scale of one to 10, with one being “numb” and 10 being “out of your mind”, shouldn’t we speak in the language our dermatologis’s speak. Learn more about Pain Scoring.